$CBIH
Cannabis Bioscience International Holdings, Inc.

2024 Q1 Form 10-Q Financial Statement

#000168316824000433 Filed on January 25, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023 Q3
Revenue $36.41K $63.75K $72.82K
YoY Change -28.96% -22.81%
Cost Of Revenue $11.81K $15.09K $8.820K
YoY Change -51.04% 112.86%
Gross Profit $24.60K $48.66K $64.00K
YoY Change -9.32% -35.55%
Gross Profit Margin 67.57% 76.33% 87.89%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $184.6K $143.2K $240.8K
YoY Change -40.84% -44.74%
Operating Profit -$160.0K -$94.51K -$176.8K
YoY Change -43.84% -48.53%
Interest Expense $49.22K $29.92K
YoY Change 23.71% -17.54%
% of Operating Profit
Other Income/Expense, Net -$49.22K -$29.92K -$5.005K
YoY Change 23.71% -17.54%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$209.2K -$124.4K -$181.8K
YoY Change -35.56% -43.41% -14.26%
Net Earnings / Revenue -574.53% -195.19% -249.64%
Basic Earnings Per Share $0.00 $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 10.38B shares 10.33B shares 10.33B shares
Diluted Shares Outstanding 10.37B shares 10.33B shares 10.33B shares

Balance Sheet

Concept 2024 Q1 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $794.00 $337.00 $4.746K
Short-Term Investments
Other Short-Term Assets $598.00
YoY Change
Inventory
Prepaid Expenses
Receivables $17.04K $19.40K
Other Receivables
Total Short-Term Assets $18.43K $19.74K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $75.54K $82.10K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $18.43K $19.74K
Total Long-Term Assets $75.54K $82.10K
Total Assets $93.97K $101.8K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due $7.054K $12.08K
YoY Change
Total Short-Term Liabilities $801.0K $660.3K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $249.5K $249.5K
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $269.0K $283.4K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $801.0K $660.3K
Total Long-Term Liabilities $269.0K $283.4K
Total Liabilities $1.070M $943.7K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$5.198M -$4.989M
YoY Change
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$976.1K -$841.9K -$717.5K
YoY Change
Total Liabilities & Shareholders Equity $93.97K $101.8K
YoY Change

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$209.2K -$124.4K -$181.8K
YoY Change -35.56% -43.41% -14.26%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$74.62K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $70.45K
YoY Change
NET CHANGE
Cash From Operating Activities -$74.62K
Cash From Investing Activities
Cash From Financing Activities $70.45K
Net Change In Cash -$4.167K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$74.62K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--05-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001411057
CY2022Q3 CBIH Change In Value Of Common Stock
ChangeInValueOfCommonStock
usd
CY2022Q3 CBIH Exchange Of Common Stock For Series B Preferred
ExchangeOfCommonStockForSeriesBPreferred
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-11-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
333-267039
dei Entity Registrant Name
EntityRegistrantName
CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
CO
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-4901299
dei Entity Address Address Line1
EntityAddressAddressLine1
6201 Bonhomme Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 466S
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77036
dei City Area Code
CityAreaCode
214
dei Local Phone Number
LocalPhoneNumber
733-0868
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10381749347 shares
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
337 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8913 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
19403 usd
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10549 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
19739 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
19462 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
82102 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23920 usd
CY2023Q4 us-gaap Assets
Assets
101842 usd
CY2023Q2 us-gaap Assets
Assets
43382 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
213521 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
111299 usd
CY2023Q4 us-gaap Bank Overdrafts
BankOverdrafts
3808 usd
CY2023Q2 us-gaap Bank Overdrafts
BankOverdrafts
0 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 usd
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
28641 usd
CY2023Q4 CBIH Related Party Payables
RelatedPartyPayables
224717 usd
CY2023Q2 CBIH Related Party Payables
RelatedPartyPayables
105173 usd
CY2023Q4 us-gaap Other Short Term Borrowings
OtherShortTermBorrowings
151267 usd
CY2023Q2 us-gaap Other Short Term Borrowings
OtherShortTermBorrowings
121407 usd
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
12079 usd
CY2023Q2 us-gaap Loans Payable Current
LoansPayableCurrent
14592 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
54915 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4435 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
660307 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
385547 usd
CY2023Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
249500 usd
CY2023Q2 us-gaap Long Term Loans Payable
LongTermLoansPayable
249500 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
33920 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
283420 usd
CY2023Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
249500 usd
CY2023Q4 us-gaap Liabilities
Liabilities
943726 usd
CY2023Q2 us-gaap Liabilities
Liabilities
635047 usd
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10331749347 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10059677919 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4147071 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4091071 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4988956 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4682736 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-841885 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-591665 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
101842 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
43382 usd
CY2023Q4 us-gaap Revenues
Revenues
63748 usd
CY2022Q4 us-gaap Revenues
Revenues
82581 usd
us-gaap Revenues
Revenues
136569 usd
us-gaap Revenues
Revenues
219162 usd
CY2023Q4 us-gaap Cost Of Revenue
CostOfRevenue
15092 usd
CY2022Q4 us-gaap Cost Of Revenue
CostOfRevenue
7090 usd
us-gaap Cost Of Revenue
CostOfRevenue
23912 usd
us-gaap Cost Of Revenue
CostOfRevenue
53324 usd
CY2023Q4 us-gaap Gross Profit
GrossProfit
48656 usd
CY2022Q4 us-gaap Gross Profit
GrossProfit
75491 usd
us-gaap Gross Profit
GrossProfit
112656 usd
us-gaap Gross Profit
GrossProfit
165838 usd
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8407 usd
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20969 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
53376 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
53505 usd
CY2023Q4 us-gaap Labor And Related Expense
LaborAndRelatedExpense
46326 usd
CY2022Q4 us-gaap Labor And Related Expense
LaborAndRelatedExpense
189158 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
141980 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
363007 usd
CY2023Q4 us-gaap Professional Fees
ProfessionalFees
45028 usd
CY2022Q4 us-gaap Professional Fees
ProfessionalFees
16022 usd
us-gaap Professional Fees
ProfessionalFees
107422 usd
us-gaap Professional Fees
ProfessionalFees
108144 usd
CY2023Q4 us-gaap Officers Compensation
OfficersCompensation
12000 usd
CY2022Q4 us-gaap Officers Compensation
OfficersCompensation
13500 usd
us-gaap Officers Compensation
OfficersCompensation
24000 usd
us-gaap Officers Compensation
OfficersCompensation
25500 usd
CY2023Q4 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
31210 usd
CY2022Q4 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
17902 usd
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
52163 usd
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
36148 usd
CY2023Q4 us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
197 usd
CY2022Q4 us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
1548 usd
us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
1898 usd
us-gaap Travel And Entertainment Expense
TravelAndEntertainmentExpense
3139 usd
CY2023Q4 us-gaap Operating Expenses
OperatingExpenses
143168 usd
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
259099 usd
us-gaap Operating Expenses
OperatingExpenses
380839 usd
us-gaap Operating Expenses
OperatingExpenses
589443 usd
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-94512 usd
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-183608 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-268182 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-423605 usd
CY2023Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2022Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
41666 usd
CY2023Q4 us-gaap Interest Expense
InterestExpense
29916 usd
CY2022Q4 us-gaap Interest Expense
InterestExpense
36278 usd
us-gaap Interest Expense
InterestExpense
38035 usd
us-gaap Interest Expense
InterestExpense
49978 usd
CY2023Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-29916 usd
CY2022Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-36278 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-38035 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8312 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-124428 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-219886 usd
us-gaap Net Income Loss
NetIncomeLoss
-306217 usd
us-gaap Net Income Loss
NetIncomeLoss
-431917 usd
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10331749347 shares
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10331749347 shares
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8090501599 shares
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8090501599 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10331749347 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10331749347 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8784573124 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8784573124 shares
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00002
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00002
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00004
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00004
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00003
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00003
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00005
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00005
us-gaap Net Income Loss
NetIncomeLoss
-306217 usd
us-gaap Net Income Loss
NetIncomeLoss
-431917 usd
CBIH Amortization Of Rightofuseasset And Liability
AmortizationOfRightofuseassetAndLiability
58183 usd
CBIH Amortization Of Rightofuseasset And Liability
AmortizationOfRightofuseassetAndLiability
3766 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-0 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
41666 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8854 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
27635 usd
CBIH Bank Overdraft Cash Flow
BankOverdraftCashFlow
3808 usd
CBIH Bank Overdraft Cash Flow
BankOverdraftCashFlow
0 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
102220 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4354 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-28641 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-295867 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-509337 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
75000 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
387666 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
19000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
-0 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
29860 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
63829 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
119544 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
49949 usd
CBIH Change In Lease Liability
ChangeInLeaseLiability
84400 usd
CBIH Change In Lease Liability
ChangeInLeaseLiability
0 usd
us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
2513 usd
us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
-0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
287291 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
501444 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8576 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7893 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8913 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31982 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
337 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24089 usd
us-gaap Interest Paid Net
InterestPaidNet
35697 usd
us-gaap Interest Paid Net
InterestPaidNet
25037 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-591665 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
74997 usd
CY2023Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
19000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-181789 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-717456 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-124428 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-841885 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-361052 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
75000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-212030 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-498081 usd
CY2022Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
312666 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-219886 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-405301 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84A_eus-gaap--UseOfEstimates_zDvgzGe9urUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_863_zbSqV2zFVnUc">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Making estimates requires management to exercise significant judgment. Certain of these estimates could be affected by external conditions, including those unique to the Company’s businesses, and general economic conditions. These external conditions could have an effect on the Company’s estimates that could cause actual results to differ materially from its estimates. Actual results could differ from those estimates. The Company re-evaluates all of its accounting estimates at least quarterly based on these conditions and records adjustments when necessary. Significant estimates relied upon in preparing these statements include revenue recognition, accounts receivable reserves, accrued expenses, share-based compensation and the recoverability of the Company’s net deferred tax assets and any related valuation allowance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_841_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zrVnr4Bprhxg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86E_zxBxTfJjRCJ4">Reclassification</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts in the prior consolidated financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no impact on the results of operations, changes in equity, or cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
0 usd
CY2023Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
0 usd
CY2023Q2 CBIH Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
131467 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
82102 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.50 pure
CY2023Q2 CBIH Operating Lease Right Of Use Asset Before Accumulated Amortization
OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization
155387 usd
CY2023Q4 CBIH Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
-0 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
us-gaap Net Income Loss
NetIncomeLoss
-306217 usd
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
295867 usd
CBIH Working Capital
WorkingCapital
-640567 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4988956 usd
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
12079 usd
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
14592 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
249500 usd
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
249500 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
261579 usd
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
264092 usd
CY2023Q4 CBIH Operating Lease Right Of Use Asset Before Accumulated Amortization
OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization
82102 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23920 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
54915 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4435 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
33920 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
88835 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
4435 usd
CY2023Q4 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
31210 usd
CY2022Q4 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
17902 usd
CY2023Q4 us-gaap Revenues
Revenues
63748 usd
CY2022Q4 us-gaap Revenues
Revenues
82581 usd
us-gaap Revenues
Revenues
136569 usd
us-gaap Revenues
Revenues
219162 usd
CY2023Q4 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
20010000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10331749347 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10331749347 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10059677919 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10059677919 shares
us-gaap Foreign Currency Transaction Gain Loss After Tax
ForeignCurrencyTransactionGainLossAfterTax
112656 usd
us-gaap Foreign Currency Transaction Gain Loss After Tax
ForeignCurrencyTransactionGainLossAfterTax
165839 usd
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
4891136 usd
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
3229732 usd
CBIH Operating Leases Rent Expense Monthly Payment
OperatingLeasesRentExpenseMonthlyPayment
3382 usd
CY2020Q3 CBIH Operating Leases Rent Expense Monthly Payment
OperatingLeasesRentExpenseMonthlyPayment
3529 usd
CY2021Q3 CBIH Operating Leases Rent Expense Monthly Payment
OperatingLeasesRentExpenseMonthlyPayment
3676 usd
CY2022Q3 CBIH Operating Leases Rent Expense Monthly Payment
OperatingLeasesRentExpenseMonthlyPayment
3823 usd
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
On March 23, 2023, the Company amended the lease to extend its term to June 30, 2024, at a base rent of $4,779 per month. On September 5, 2023, the lease was amended to extend its term to June 30, 2025, at rentals of $0 per month for the two months ended November 30, 2023, $$4,779 per month for the 10 months ending June 30, 2024, and $4,926 per month for the 12 months ending June 30, 2025.
us-gaap Liabilities And Stockholders Equity Average Amount Outstanding
LiabilitiesAndStockholdersEquityAverageAmountOutstanding
224717 usd
us-gaap Liabilities And Stockholders Equity Average Amount Outstanding
LiabilitiesAndStockholdersEquityAverageAmountOutstanding
105173 usd
CY2023Q4 CBIH Off Balance Sheet Arrangements
OffBalanceSheetArrangements
0 usd

Files In Submission

Name View Source Status
cbih-20231130_cal.xml Edgar Link unprocessable
cbih-20231130_lab.xml Edgar Link unprocessable
cbih-20231130_def.xml Edgar Link unprocessable
cbih-20231130_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0001683168-24-000433-index-headers.html Edgar Link pending
0001683168-24-000433-index.html Edgar Link pending
0001683168-24-000433.txt Edgar Link pending
0001683168-24-000433-xbrl.zip Edgar Link pending
cannabis_ex3100.htm Edgar Link pending
cannabis_ex3200.htm Edgar Link pending
cannabis_i10q-113023.htm Edgar Link pending
cbih-20231130.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cannabis_i10q-113023_htm.xml Edgar Link completed